Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases

Cisplatin is the mainstay of first-line treatment for advanced non-small cell lung cancer (NSCLC). Accumulating evidence suggests that flavonoids inhibit histone deacetylase (HDAC) to mediate their anticancer effect in various cancer types. The study was conducted to investigate the inhibition of HD...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Life sciences (1973) 2020-10, Vol.258, p.118211, Article 118211
Hauptverfasser: Yan, Wei, Wu, Tracy H.Y., Leung, Sharon S.Y., To, Kenneth K.W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 118211
container_title Life sciences (1973)
container_volume 258
creator Yan, Wei
Wu, Tracy H.Y.
Leung, Sharon S.Y.
To, Kenneth K.W.
description Cisplatin is the mainstay of first-line treatment for advanced non-small cell lung cancer (NSCLC). Accumulating evidence suggests that flavonoids inhibit histone deacetylase (HDAC) to mediate their anticancer effect in various cancer types. The study was conducted to investigate the inhibition of HDAC and the modulation of apoptotic and cell cycle regulatory genes by selected flavonoids to potentiate the anticancer effect of cisplatin. Combinations of cisplatin and selected flavonoids were investigated in three NSCLC cell lines (A549, H460, and H1299). Sulforhodamine B assay was used to evaluate cytotoxicity of drug combinations. Western blot analysis was conducted to evaluate histone acetylation. Flow cytometric assays were used to investigate the apoptotic and cell cycle effect. Chromatin immunoprecipitation assay was performed to elucidate the binding of transcription factors to promoters of selected apoptotic and cell cycle regulatory genes. Apigenin was found to exhibit the strongest HDAC inhibitory effect among all flavonoids tested. Cisplatin-apigenin combination was shown to produce significantly more S phase prolongation and G2/M cell cycle arrest, and apoptosis compared with cisplatin or apigenin alone, by inducing p21 and PUMA, respectively. More pronounced effect was observed in p53-proficient than p53-null NSCLC cells. Mechanistically, apigenin was found to reduce the binding of HDAC1 but increase the association of RNA polymerase II and Sp1 to p21 and PUMA promoters. Our findings provide a better insight about the mechanism contributing to the HDAC inhibitory effect of apigenin to potentiate anticancer effect of cisplatin by inducing apoptosis and cell cycle arrest. [Display omitted]
doi_str_mv 10.1016/j.lfs.2020.118211
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2505725984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0024320520309632</els_id><sourcerecordid>2505725984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c358t-efa299af2bdb307223f78490ceac83e88bd24bb9ef2073fa196c6d89aeb615c53</originalsourceid><addsrcrecordid>eNp9kMtqAyEUhqW00DTtA3QndD2plzjj0FUJvUGgm3YtjnNMDBOdqgnkCfraNSTrguhR_u8c-RC6p2RGCa0fN7PBphkjrNypZJReoAmVTVuRmtNLNCGEzSvOiLhGNyltCCFCNHyCfl8HvQ8-uD7hMWTw2ekMPdalMNobiFib7PYuH3Cw2Lg0Djo7j8vywVdpq4cBGyjbsPMrfGaOD-mYKWAMuDuUeu06V8gVXruUgwfcgzaQD4NOkG7RldVDgrvzOUXfry9fi_dq-fn2sXheVoYLmSuwmrWttqzrO04axrht5LwlprSSHKTsejbvuhYsIw23mra1qXvZauhqKozgU_Rw6jvG8LODlNUm7KIvIxUTRDRMtHJeUvSUMjGkFMGqMbqtjgdFiTr6VhtVfKujb3XyXZinEwPl-3sHUSXjoNjoXQSTVR_cP_Qf2JWLwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2505725984</pqid></control><display><type>article</type><title>Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Yan, Wei ; Wu, Tracy H.Y. ; Leung, Sharon S.Y. ; To, Kenneth K.W.</creator><creatorcontrib>Yan, Wei ; Wu, Tracy H.Y. ; Leung, Sharon S.Y. ; To, Kenneth K.W.</creatorcontrib><description>Cisplatin is the mainstay of first-line treatment for advanced non-small cell lung cancer (NSCLC). Accumulating evidence suggests that flavonoids inhibit histone deacetylase (HDAC) to mediate their anticancer effect in various cancer types. The study was conducted to investigate the inhibition of HDAC and the modulation of apoptotic and cell cycle regulatory genes by selected flavonoids to potentiate the anticancer effect of cisplatin. Combinations of cisplatin and selected flavonoids were investigated in three NSCLC cell lines (A549, H460, and H1299). Sulforhodamine B assay was used to evaluate cytotoxicity of drug combinations. Western blot analysis was conducted to evaluate histone acetylation. Flow cytometric assays were used to investigate the apoptotic and cell cycle effect. Chromatin immunoprecipitation assay was performed to elucidate the binding of transcription factors to promoters of selected apoptotic and cell cycle regulatory genes. Apigenin was found to exhibit the strongest HDAC inhibitory effect among all flavonoids tested. Cisplatin-apigenin combination was shown to produce significantly more S phase prolongation and G2/M cell cycle arrest, and apoptosis compared with cisplatin or apigenin alone, by inducing p21 and PUMA, respectively. More pronounced effect was observed in p53-proficient than p53-null NSCLC cells. Mechanistically, apigenin was found to reduce the binding of HDAC1 but increase the association of RNA polymerase II and Sp1 to p21 and PUMA promoters. Our findings provide a better insight about the mechanism contributing to the HDAC inhibitory effect of apigenin to potentiate anticancer effect of cisplatin by inducing apoptosis and cell cycle arrest. [Display omitted]</description><identifier>ISSN: 0024-3205</identifier><identifier>EISSN: 1879-0631</identifier><identifier>DOI: 10.1016/j.lfs.2020.118211</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Acetylation ; Anticancer properties ; Antitumor activity ; Apigenin ; Apoptosis ; Assaying ; Binding ; Cell cycle ; Chromatin ; Cisplatin ; Cyclin-dependent kinase inhibitor p21 ; Cytotoxicity ; DNA-directed RNA polymerase ; Flavonoids ; Flow cytometry ; Genes ; Histone deacetylase ; Histone deacetylases ; Histones ; Immunoprecipitation ; Lung cancer ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; p53 Protein ; Prolongation ; Promoters ; RNA polymerase ; RNA polymerase II ; S phase ; Small cell lung carcinoma ; Sp1 protein ; Sulforhodamine ; Toxicity ; Transcription factors</subject><ispartof>Life sciences (1973), 2020-10, Vol.258, p.118211, Article 118211</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright Elsevier BV Oct 1, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c358t-efa299af2bdb307223f78490ceac83e88bd24bb9ef2073fa196c6d89aeb615c53</citedby><cites>FETCH-LOGICAL-c358t-efa299af2bdb307223f78490ceac83e88bd24bb9ef2073fa196c6d89aeb615c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lfs.2020.118211$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Yan, Wei</creatorcontrib><creatorcontrib>Wu, Tracy H.Y.</creatorcontrib><creatorcontrib>Leung, Sharon S.Y.</creatorcontrib><creatorcontrib>To, Kenneth K.W.</creatorcontrib><title>Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases</title><title>Life sciences (1973)</title><description>Cisplatin is the mainstay of first-line treatment for advanced non-small cell lung cancer (NSCLC). Accumulating evidence suggests that flavonoids inhibit histone deacetylase (HDAC) to mediate their anticancer effect in various cancer types. The study was conducted to investigate the inhibition of HDAC and the modulation of apoptotic and cell cycle regulatory genes by selected flavonoids to potentiate the anticancer effect of cisplatin. Combinations of cisplatin and selected flavonoids were investigated in three NSCLC cell lines (A549, H460, and H1299). Sulforhodamine B assay was used to evaluate cytotoxicity of drug combinations. Western blot analysis was conducted to evaluate histone acetylation. Flow cytometric assays were used to investigate the apoptotic and cell cycle effect. Chromatin immunoprecipitation assay was performed to elucidate the binding of transcription factors to promoters of selected apoptotic and cell cycle regulatory genes. Apigenin was found to exhibit the strongest HDAC inhibitory effect among all flavonoids tested. Cisplatin-apigenin combination was shown to produce significantly more S phase prolongation and G2/M cell cycle arrest, and apoptosis compared with cisplatin or apigenin alone, by inducing p21 and PUMA, respectively. More pronounced effect was observed in p53-proficient than p53-null NSCLC cells. Mechanistically, apigenin was found to reduce the binding of HDAC1 but increase the association of RNA polymerase II and Sp1 to p21 and PUMA promoters. Our findings provide a better insight about the mechanism contributing to the HDAC inhibitory effect of apigenin to potentiate anticancer effect of cisplatin by inducing apoptosis and cell cycle arrest. [Display omitted]</description><subject>Acetylation</subject><subject>Anticancer properties</subject><subject>Antitumor activity</subject><subject>Apigenin</subject><subject>Apoptosis</subject><subject>Assaying</subject><subject>Binding</subject><subject>Cell cycle</subject><subject>Chromatin</subject><subject>Cisplatin</subject><subject>Cyclin-dependent kinase inhibitor p21</subject><subject>Cytotoxicity</subject><subject>DNA-directed RNA polymerase</subject><subject>Flavonoids</subject><subject>Flow cytometry</subject><subject>Genes</subject><subject>Histone deacetylase</subject><subject>Histone deacetylases</subject><subject>Histones</subject><subject>Immunoprecipitation</subject><subject>Lung cancer</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>p53 Protein</subject><subject>Prolongation</subject><subject>Promoters</subject><subject>RNA polymerase</subject><subject>RNA polymerase II</subject><subject>S phase</subject><subject>Small cell lung carcinoma</subject><subject>Sp1 protein</subject><subject>Sulforhodamine</subject><subject>Toxicity</subject><subject>Transcription factors</subject><issn>0024-3205</issn><issn>1879-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMtqAyEUhqW00DTtA3QndD2plzjj0FUJvUGgm3YtjnNMDBOdqgnkCfraNSTrguhR_u8c-RC6p2RGCa0fN7PBphkjrNypZJReoAmVTVuRmtNLNCGEzSvOiLhGNyltCCFCNHyCfl8HvQ8-uD7hMWTw2ekMPdalMNobiFib7PYuH3Cw2Lg0Djo7j8vywVdpq4cBGyjbsPMrfGaOD-mYKWAMuDuUeu06V8gVXruUgwfcgzaQD4NOkG7RldVDgrvzOUXfry9fi_dq-fn2sXheVoYLmSuwmrWttqzrO04axrht5LwlprSSHKTsejbvuhYsIw23mra1qXvZauhqKozgU_Rw6jvG8LODlNUm7KIvIxUTRDRMtHJeUvSUMjGkFMGqMbqtjgdFiTr6VhtVfKujb3XyXZinEwPl-3sHUSXjoNjoXQSTVR_cP_Qf2JWLwg</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Yan, Wei</creator><creator>Wu, Tracy H.Y.</creator><creator>Leung, Sharon S.Y.</creator><creator>To, Kenneth K.W.</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20201001</creationdate><title>Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases</title><author>Yan, Wei ; Wu, Tracy H.Y. ; Leung, Sharon S.Y. ; To, Kenneth K.W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c358t-efa299af2bdb307223f78490ceac83e88bd24bb9ef2073fa196c6d89aeb615c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetylation</topic><topic>Anticancer properties</topic><topic>Antitumor activity</topic><topic>Apigenin</topic><topic>Apoptosis</topic><topic>Assaying</topic><topic>Binding</topic><topic>Cell cycle</topic><topic>Chromatin</topic><topic>Cisplatin</topic><topic>Cyclin-dependent kinase inhibitor p21</topic><topic>Cytotoxicity</topic><topic>DNA-directed RNA polymerase</topic><topic>Flavonoids</topic><topic>Flow cytometry</topic><topic>Genes</topic><topic>Histone deacetylase</topic><topic>Histone deacetylases</topic><topic>Histones</topic><topic>Immunoprecipitation</topic><topic>Lung cancer</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>p53 Protein</topic><topic>Prolongation</topic><topic>Promoters</topic><topic>RNA polymerase</topic><topic>RNA polymerase II</topic><topic>S phase</topic><topic>Small cell lung carcinoma</topic><topic>Sp1 protein</topic><topic>Sulforhodamine</topic><topic>Toxicity</topic><topic>Transcription factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yan, Wei</creatorcontrib><creatorcontrib>Wu, Tracy H.Y.</creatorcontrib><creatorcontrib>Leung, Sharon S.Y.</creatorcontrib><creatorcontrib>To, Kenneth K.W.</creatorcontrib><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Life sciences (1973)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yan, Wei</au><au>Wu, Tracy H.Y.</au><au>Leung, Sharon S.Y.</au><au>To, Kenneth K.W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases</atitle><jtitle>Life sciences (1973)</jtitle><date>2020-10-01</date><risdate>2020</risdate><volume>258</volume><spage>118211</spage><pages>118211-</pages><artnum>118211</artnum><issn>0024-3205</issn><eissn>1879-0631</eissn><abstract>Cisplatin is the mainstay of first-line treatment for advanced non-small cell lung cancer (NSCLC). Accumulating evidence suggests that flavonoids inhibit histone deacetylase (HDAC) to mediate their anticancer effect in various cancer types. The study was conducted to investigate the inhibition of HDAC and the modulation of apoptotic and cell cycle regulatory genes by selected flavonoids to potentiate the anticancer effect of cisplatin. Combinations of cisplatin and selected flavonoids were investigated in three NSCLC cell lines (A549, H460, and H1299). Sulforhodamine B assay was used to evaluate cytotoxicity of drug combinations. Western blot analysis was conducted to evaluate histone acetylation. Flow cytometric assays were used to investigate the apoptotic and cell cycle effect. Chromatin immunoprecipitation assay was performed to elucidate the binding of transcription factors to promoters of selected apoptotic and cell cycle regulatory genes. Apigenin was found to exhibit the strongest HDAC inhibitory effect among all flavonoids tested. Cisplatin-apigenin combination was shown to produce significantly more S phase prolongation and G2/M cell cycle arrest, and apoptosis compared with cisplatin or apigenin alone, by inducing p21 and PUMA, respectively. More pronounced effect was observed in p53-proficient than p53-null NSCLC cells. Mechanistically, apigenin was found to reduce the binding of HDAC1 but increase the association of RNA polymerase II and Sp1 to p21 and PUMA promoters. Our findings provide a better insight about the mechanism contributing to the HDAC inhibitory effect of apigenin to potentiate anticancer effect of cisplatin by inducing apoptosis and cell cycle arrest. [Display omitted]</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.lfs.2020.118211</doi></addata></record>
fulltext fulltext
identifier ISSN: 0024-3205
ispartof Life sciences (1973), 2020-10, Vol.258, p.118211, Article 118211
issn 0024-3205
1879-0631
language eng
recordid cdi_proquest_journals_2505725984
source Elsevier ScienceDirect Journals Complete
subjects Acetylation
Anticancer properties
Antitumor activity
Apigenin
Apoptosis
Assaying
Binding
Cell cycle
Chromatin
Cisplatin
Cyclin-dependent kinase inhibitor p21
Cytotoxicity
DNA-directed RNA polymerase
Flavonoids
Flow cytometry
Genes
Histone deacetylase
Histone deacetylases
Histones
Immunoprecipitation
Lung cancer
Non-small cell lung cancer
Non-small cell lung carcinoma
p53 Protein
Prolongation
Promoters
RNA polymerase
RNA polymerase II
S phase
Small cell lung carcinoma
Sp1 protein
Sulforhodamine
Toxicity
Transcription factors
title Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A52%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Flavonoids%20potentiated%20anticancer%20activity%20of%20cisplatin%20in%20non-small%20cell%20lung%20cancer%20cells%20in%20vitro%20by%20inhibiting%20histone%20deacetylases&rft.jtitle=Life%20sciences%20(1973)&rft.au=Yan,%20Wei&rft.date=2020-10-01&rft.volume=258&rft.spage=118211&rft.pages=118211-&rft.artnum=118211&rft.issn=0024-3205&rft.eissn=1879-0631&rft_id=info:doi/10.1016/j.lfs.2020.118211&rft_dat=%3Cproquest_cross%3E2505725984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2505725984&rft_id=info:pmid/&rft_els_id=S0024320520309632&rfr_iscdi=true